MondayLunchLive
The 2026 Picchi Award recipients present their winning PhD research across three categories. The winners receive $10,000 each from The Picchi Brothers Foundation, which aims to inspire and encourage the next generation of cancer research leaders. The prize provides the opportunity to travel internationally for conferences or collaborative works to support their development towards research independence.
Clinical Science category awarded to Sarah Glewis.
Population Health category awarded to Amelia Hyatt.
Basic Science category awarded to Vicky Qin.
Watch on demand
Session recording
Recording guide
Explore the session
Chapter markers are built into the player. Select a chapter to open that point of the recording on YouTube in a new tab.
01 Welcome, acknowledgements & prize overview (opens in a new tab) 0:00 →
02 Sarah Glewis — Pharmacogenomics (DPYD & UGT) presentation and Q&A (opens in a new tab) 3:50 →
03 Amelia Hyatt — Cervical cancer policy, PACE tool & political economy (opens in a new tab) 18:56 →
04 Q&A, Australia context & transition to final speaker (opens in a new tab) 34:10 →
05 Vicky Qin — CAR T research presentation and closing remarks (opens in a new tab) 36:26 →
At a glance
The session in brief
Originally held
Monday 12 October 2026
Online.
Who this is for
Researchers, nurses, consumers, allied health, admin
Anyone interested in supporting emerging cancer researchers and discoveries.
Contributors
Chair and speakers
Chair
Professor Mark Rosenthal
Director, Parkville Cancer Clinical Trials Unit (PCCTU); Medical Oncologist, Peter MacCallum Cancer Centre and Royal Melbourne Hospital
Professor Mark Rosenthal trained as a medical oncologist in Melbourne and Sydney, Australia. He received a Doctorate of Philosophy for a thesis examining the molecular genetics of colon cancer conducted at the Ludwig Institute for Cancer Research (1992-1996). He completed post-graduate training at New York University Medical Centre, New York, USA (1996-98) was a Senior Staff Specialist in the Department of Medical Oncology, Royal Melbourne Hospital (1998-2016) and Professor Director of the Department from 2006-2016. He was Chair and Chief Medical Officer of Cancer Trials Australia (2006-2016), inaugural Chair of the Cooperative Trials Group for Neuro-Oncology (2007-2017) and was the Clinical Trials Lead for the Victorian Comprehensive Cancer Centre (2016-20)
Professor Rosenthal is currently a Senior Staff Specialist in the Department of Medical Oncology at the Peter MacCallum Cancer Centre, Medical and Trials Lead for Neuro-oncology and Director of the Parkville Cancer Clinical Trials Unit. He has published over 170 peer-reviewed manuscripts and has been awarded over $30 million in competitive research grants. His major interests include neuro-oncology and clinical trials.
Speaker
Sarah Glewis
Senior Pharmacogenomics Pharmacist and PhD Candidate
Sarah led PACIFIC-PGx, an early Australian multicentre pharmacogenomics clinical trial, and manages the follow-on PRECISION trial with expanded pharmacogenomics testing. Her research supported Medicare reimbursement for pre-emptive DPYD gene testing. During her PhD, she has published eight first-author papers and has been invited to speak at major national and international conferences. Her work has been recognised through ISOPP research funding, the Victorian Healthcare Awards, and the 2026 ISOPP Achievement Award.
Speaker
Amelia Hyatt
Senior Research Fellow, Peter MacCallum Cancer Centre; Honorary Fellow at the University of Melbourne
Amelia specialises in health policy, implementation science and global cancer control. Her research focuses on translating evidence into policy and practice to strengthen cancer care, improve health equity and address systemic barriers to better outcomes. She works closely with government, health services and community stakeholders in Australia and across the South Pacific, with a particular focus on strengthening cancer control systems and policy capacity.
Speaker
Dr Vicky Mengfei Qin
PhD Graduate, Peter MacCallum Cancer Centre and the University of Melbourne
Dr Qin's research developed a novel CAR-T-cell strategy that harnesses immunosuppressive molecules within the tumour microenvironment to enhance T-cell metabolic fitness and anti-tumour activity. This work offers a promising approach to improve CAR-T-cell therapy for solid tumours.
Resource details
This course is brought to you by
